Bharatbook.com announces a new report on "Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma" 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations.
Mumbai, Maharashtra, India., April 4, 2014 - (PressReleasePoint) - Bharat Book Bureau presents the new report, on "Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma". I2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations.
2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. These regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. The implications of new price-reversions are going to have many facets and will change conventional business models. In this many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer.
Innovation Takes the Driver's Seat: While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'. Japanese innovators will now become more serious and selective in their R&D approach. Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5). This trend to prevail in the coming years.
The 138 pages report contains the detailed discussion of Japan biopharmaceutical market – which includes- Our view on the impact of 2014 price cuts on generic companies and innovator companies and detailed discussion on key attributes (consolidation activities, potential of R & D pipeline candidates, generic threat in domestic Japan market etc…) of leading Japanese innovator companies- Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Kyorin, Kyowa hakko Kirin, Mitsubishi Tanabe, Shionogi, Takeda and leading Japanese generic companies- Nippon Chemiphar, Sawai and Towa.
-New Price-Cuts – A Double Punch To The Innovators!
-New Slabs For Nhi Price Cuts For Long-listed Drugs
-Expense Vs. Protability Of Japanese Innovators
-Another Blow For Innovators In Not Institutionalizing The ‘Innovation Premium’
Pressure To Generic Discount Further Increased
Upcoming New Generics
New Drug Prices For Existing Ge Drugs
Listing Of GE Drugs by Both GE Name And Brand To Promote Discounting
Finding New Avenues Of Cost Saving Are Inevitable For GE Cos
Innovators Need To Redene Long-Listed Products Strategies
Consolidation Activities To Will Witness A Boost
About Author Bio: I am working with a market research company which provides market research reports , company profiles, custom research, industry analysis, country reports , business reports, online databases and the report on "Global Pharmaceutical & Biotechnology Outlook 2014: Japan Pharma" etc. Through our industry analysis you can identify opportunities, analyze the requirements of the customers and study the competition sector wise.
Press Contact: Sandhya Nair 808, Real Tech Park,8th Floor, Sector - 30A,Vashi, Navi Mumbai - 400703, INDIA. +912227810772, 27810 *******@b**r**b**k.com Email partially hidden to block spam. Please use the contact form here.